Indeed, a recent phase III clinical trial (ADAURA [NCT02511106]) assessed the efficacy and safety of a 3rd-generation EGFR-TKI, osimertinib, which had superior efficacy when compared to EGFR-TKI (gefitinib/erlotinib) in treatment-naïve patients with EGFR-mutated advanced NSCLC [10]. Here, EGFR is linked to non-small cell lung carcinoma.